Market capitalization | $14.71m |
Enterprise Value | $12.37m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 5.44 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-689.00k |
Cash position | $2.34m |
EPS (TTM) EPS | $-0.07 |
Short interest | 1.02% |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast XTL Biopharmaceuticals Ltd. Sponsored ADR:
1 Analyst has issued a forecast XTL Biopharmaceuticals Ltd. Sponsored ADR:
Mar '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -0.69 -0.69 |
22%
22%
|
Net Profit | -0.38 -0.38 |
86%
86%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
XTL Biopharmaceuticals Ltd. focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.
Head office | Israel |
CEO | Shlomo Shalev |
Employees | 8 |
Founded | 1993 |
Website | www.xtlbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.